Related Experiment Video

Updated: Jan 2, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K

Salinomycin targets the genome of radioresistant cells in glioblastomas

Steven L Carroll1, Jody Fromm Longo1

  • 1Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.

Neuro-Oncology
|December 1, 2019
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.0K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.0K

Related Experiment Videos

Last Updated: Jan 2, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.0K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

Articles linked to this work by shared authors, journal, and citation graph.

Brain age gradients as intermediate phenotypes linking plasma p-tau217 to cognition in community-dwelling older adults.

NPJ dementia·2026

Immune imbalance in the human hippocampus in PTSD revealed by single-nucleus transcriptomics.

Frontiers in immunology·2026

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Single-nucleus transcriptomics reveals sepsis-related neurovascular dysfunction in the human hippocampus.

Frontiers in immunology·2025

Early versus late venous thromboembolism in patients with newly diagnosed high-grade gliomas.

Neuro-oncology·2026

EGFRvIII overexpression and loss of mouse-specific CDKN2A in glial cells leads to spontaneous gliomagenesis in a novel mouse model.

Neuro-oncology·2026

EGFRvIII-Positive Glioblastoma: Structural Rewiring, Immune Microenvironmental Remodeling, and Therapeutic Resistance.

Neuro-oncology·2026

Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights.

Neuro-oncology·2026

MRI-Based Machine Learning to Differentiate True Progression from Pseudoprogression in Glioblastoma: An Updated Systematic Review and Meta-Analysis.

Neuro-oncology·2026

Biomarker-guided treatment strategies for patients with gliomas in clinical practice.

Neuro-oncology·2026

Genetic Variation Disrupts RNA Structural Repression of Cryptic Splice Sites.

Research square·2026

High-throughput identification of chromatin-opening transcription factors.

bioRxiv : the preprint server for biology·2026

Multi-omic long-read sequencing reveals nucleosome control of transcriptional fidelity at the isoform level.

bioRxiv : the preprint server for biology·2026

Structural variants from donor-specific assemblies affect recurrent chromatin contact divergence in humans.

bioRxiv : the preprint server for biology·2026

PHC2-Dependent PRC1 Assemblies Stabilize Motor Neuron Hox Codes.

bioRxiv : the preprint server for biology·2026

Heterochromatin protein 1α acts as an essential stabilizer of chromatin packing domains.

bioRxiv : the preprint server for biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us